54274-80-5

Usage

Uses

Used in Organic Synthesis:
(1R,4R)-methyl 4-formylcyclohexanecarboxylate is used as a reagent in organic synthesis for its ability to contribute to the formation of complex organic molecules. Its unique structure allows it to be a key component in the production of pharmaceuticals and agrochemicals, where its chiral center and formyl group are crucial for the synthesis of biologically active compounds.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (1R,4R)-methyl 4-formylcyclohexanecarboxylate is used as an intermediate in the synthesis of drugs. Its specific stereochemistry is essential for the development of enantiomerically pure compounds, which are often required for the desired therapeutic effects and to avoid potential side effects associated with the less active enantiomer.
Used in Agrochemical Industry:
Similarly, in the agrochemical industry, (1R,4R)-methyl 4-formylcyclohexanecarboxylate is utilized as an intermediate for the production of pesticides and other agrochemicals. Its role in creating chiral pesticides can lead to more effective and selective agents that minimize environmental impact.
Used in Fragrance Industry:
Due to its cyclohexane ring structure, (1R,4R)-methyl 4-formylcyclohexanecarboxylate also has potential applications in the fragrance industry. It can be used as a building block for creating unique and complex scents, taking advantage of its ability to contribute to the molecular structure of fragrance compounds.

InChI:InChI=1/C9H14O3/c1-12-9(11)8-4-2-7(6-10)3-5-8/h6-8H,2-5H2,1H3

Upstream product

• 891828-63-0 methyl 4-methoxymethylidene-cyclohexane-carboxylate 
• 1571-08-0 methyl 4-formylbenzoate 
• 135655-75-3 2-(4-carbomethoxyphenyl)-1,3-dioxane 
• 110928-44-4 trans-(4-hydroxymethyl)cyclohexane-1-carboxylic acid methyl ester 
• 32529-80-9 trans-1-chlorocarbonyl-4-(methoxycarbonyl)-cyclohexane 
• 66185-74-8 (1r,4r)‐4‐(hydroxymethyl)cyclohexane‐1‐carboxylic acid 

Downstream Products

• 115786-18-0 4-(5-Cyano-5-hexyl-[1,3]dioxan-2-yl)-cyclohexanecarboxylic acid methyl ester 
• 115786-19-1 4-(5-Cyano-5-nonyl-[1,3]dioxan-2-yl)-cyclohexanecarboxylic acid methyl ester 
• 1443021-72-4 C₃₂H₃₈Cl₂N₂O₆ 
• 1259393-26-4 methyl 4-(((S)-5-((3,5-bis(trifluoromethyl)-benzyl)(2-methyl-2H-tetrazol-5-yl)amino)-7,9-dimethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)methyl)-cyclohexane-1-carboxylate 
• 1587704-14-0 C₃₂H₃₈F₆N₆O₂ 
• 1346450-07-4 trans-(E/Z)-4-(hydroxyimino-methyl)-cyclohexanecarboxylic acid methyl ester 

Relevant academic research and scientific papers

CYCLOPROPYLAMINE COMPOUND AS LSD1 INHIBITOR AND USE THEREOF

Provided is a cyclopropylamine compound as lysine-specific demethylase 1 (LSD1) inhibitor, and a use thereof in preparation of drug for treating diseases associated with LSD1. The cyclopropylamine compound is a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof.

NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF

The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.

Nitrogen-containing heterocyclic compound as well as preparation method, pharmaceutical composition and application thereof

The invention provides a nitrogen-containing heterocyclic compound as well as a preparation method, a pharmaceutical composition and application thereof, and particularly provides a compound as shownin a formula I which is described in the specification,

Containing difluoro methylene key bridge of the liquid crystal compound and its preparation method and composition

The invention discloses a liquid crystal compound containing difluoro-methylene key bridge, a preparation method of the liquid crystal compound containing difluoro-methylene key bridge and a composition containing the liquid crystal compound. The liquid c

Synthesis and Biopharmaceutical Evaluation of Imatinib Analogues Featuring Unusual Structural Motifs

A convenient synthesis of imatinib, a potent inhibitor of ABL1 kinase and widely prescribed drug for the treatment of a variety of leukemias, was devised and applied to the construction of a series of novel imatinib analogues featuring a number of non-aromatic structural motifs in place of the parent molecule's phenyl moiety. These analogues were subsequently evaluated for their biopharmaceutical properties (e.g., ABL1 kinase inhibitory activity, cytotoxicity). The bicyclo[1.1.1]pentane- and cubane-containing analogues were found to possess higher themodynamic solubility, whereas cubane- and cyclohexyl-containing analogues exhibited the highest inhibitory activity against ABL1 kinase and the most potent cytotoxicity values against cancer cell lines K562 and SUP-B15. Molecular modeling was employed to rationalize the weak activity of the compounds against ABL1 kinase, and it is likely that the observed cytotoxicity of these agents arises through off-target effects.

Development of a hydrogenative reductive amination for the synthesis of evacetrapib: Unexpected benefits of water

For the synthesis of cholesteryl ester transfer protein (CETP) inhibitor evacetrapib, a hydrogenative reductive amination was chosen to join the substituted cyclohexyl subunit to the benzazepine core. The addition of water, which suppressed undesired epimerization without affecting the rate of product formation, was key to the reactions success. The process was scaled to produce more than 1100 kg of material.

Cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes as V1a antagonists

The present invention provides 4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

Counterion effects in the preparation of aldehyde-bisulfite adducts

The identification and development of an aldehyde-bisulfite adduct as an isolable starting material in the synthesis of the CETP inhibitor Evacetrapib are described. The physical properties of the sodium and potassium analogs are compared, and the extension of the scope of this study to include an investigation into the solid state properties of a range of sodium and potassium bisulfite adducts of commonly encountered aldehydes is discussed.

SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS

The invention provides certain substituted diazine and triazine compounds of the Formula (I) (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, Rcy,Cy, and t are as d

NITROGENOUS FUSED BICYCLIC COMPOUND

A novel nitrogenous fused bicyclic compound represented by the following general formula [1] or a pharmacologically acceptable salt of the compound. They have excellent SK channel blocking activity and are useful as a medicine. [I] (In the formula, R 0 represents hydrogen, halogeno, etc.; R 1 represents a group represented by the formula (a) or (b); A represents a group represented by the formula (X) or (Y); D 1 , D 2 and D 3 each represents N or CH; R 2 represents halogeno or optionally halogenated lower alkyl, etc.; R 3 represents hydrogen or lower alkyl; and Q represents lower alkylene.)